teaser
Lapatinib (Tykerb®) has been approved in Switzerland, its first European market, in combination with capecitabine for treating patients with advanced breast cancer, and in women with HER-2 positive breast cancer who are unresponsive to therapy with trastuzumab (Herceptin®).
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Approval was based on a pivotal phase III trial in women with breast cancer which found that a combination of lapatinib and capecitabine was associated with better progression-free survival than capecitabine alone (27.1 vs 18.6 weeks). Analysts suggest that lapatinib looks set to face a battle for market share with trastuzumab and that it may have an advantage in being an oral agent.
PharmaTimes 24/5/2007
